StockData
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc. (AVTX) stock

AVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/30
$7.37−0.39 (-5.03%)

Close on Nov 16, 2026Market cap $395.25MP/E –Yield –

Avalo Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Avalo Therapeutics's gross margin for the twelve months ending Sep 30, 2023 was 5.5%. For fiscal 2023 it was 33.3%, against 81.0% the year before. The highest annual figure on record is 108.4% in fiscal 2019.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 202333.3%−47.7
FY2022Dec 31, 202281.0%+8.6
FY2021Dec 31, 202172.4%−23.1
FY2020Dec 31, 202095.5%−12.9
FY2019Dec 31, 2019108.4%+54.8
FY2018Dec 31, 201853.6%−44.1
FY2017Dec 31, 201797.7%−2.3
FY2016Dec 31, 2016100.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2024Sep 30, 2024386.7%+355.9
Q3 FY2023Sep 30, 2023-4.7%−101.1
Q2 FY2023Jun 30, 2023-10.1%+41.6
Q1 FY2023Mar 31, 2023-16.0%−54.6
Q4 FY2022Dec 31, 202230.8%+124.4
Q3 FY2022Sep 30, 202296.5%+63.7
Q2 FY2022Jun 30, 2022-51.7%−149.2
Q1 FY2022Mar 31, 202238.6%−45.1
Q4 FY2021Dec 31, 2021-93.6%−188.3
Q3 FY2021Sep 30, 202132.7%−60.3
Q2 FY2021Jun 30, 202197.5%+3.4
Q1 FY2021Mar 31, 202183.7%−13.9
Q4 FY2020Dec 31, 202094.7%+0.7
Q3 FY2020Sep 30, 202093.1%−114.5
Q2 FY2020Jun 30, 202094.2%+23.4
Q1 FY2020Mar 31, 202097.6%+39.3
Q3 FY2019Sep 30, 201994.0%+70.3
Q2 FY2019Jun 30, 2019207.5%+137.3
Q1 FY2019Mar 31, 201970.8%−9.9
Q4 FY2018Dec 31, 201858.3%−8.5
Q3 FY2018Sep 30, 201823.6%−76.4
Q2 FY2018Jun 30, 201870.3%−29.7
Q1 FY2018Mar 31, 201880.7%−19.3
Q4 FY2017Dec 31, 201766.7%–
Q3 FY2017Sep 30, 2017100.0%–
Q2 FY2017Jun 30, 2017100.0%–
Q1 FY2017Mar 31, 2017100.0%–

More Avalo Therapeutics figures

See a number that looks wrong?